Abbonarsi

Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: Insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial - 07/08/11

Doi : 10.1016/j.ahj.2009.10.034 
Harvey D. White, DSc a, , Philip E. Aylward, BM, BCh b, Richard Gallo, MD c, Christoph Bode, MD d, Gabriel Steg, MD e, Steven R. Steinhubl, MD f, Gilles Montalescot, MD g

for the STEEPLE Investigators

a Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand 
b Flinders Medical Centre, Bedford Park, SA, Australia 
c Montreal Heart Institute, Université de Montréal, Montréal, Quebec, Canada 
d Department of Internal Medicine III, Cardiology and Vascular Medicine, Universitätsklinikum Freiburg, Germany 
e Service de Cardiologie, Hôpital Bichat, Paris, France 
f The Adjunct Faculty, Geisinger Clinic, Geisinger Center for Health Research, Danville, PA 
g Institut de Cardiologie (AP-HP) and INSERM Unit #856 Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France 

Reprint requests: Harvey D. White, DSc, Green Lane Cardiovascular Service, Auckland City Hospital, Private Bag 92024, Victoria St West, Auckland 1142, New Zealand.

Riassunto

Background

Major bleeding significantly impacts outcomes in patients undergoing percutaneous coronary intervention (PCI). No uniform definitions exist for major and minor bleeding. Hematomas ≥5 cm at the femoral puncture site are considered major bleeding events in some trials and minor in others. Limited information is available on the incidence and clinical relevance of hematomas ≥5 cm in PCI patients.

Methods

Data from the STEEPLE trial in patients undergoing elective PCI were used to assess the impact of hematomas ≥5 cm on ischemic outcomes (mortality, nonfatal myocardial infarction, or urgent target vessel revascularization) up to day 30 and all-cause 1-year mortality. Hematoma data were available for 3,342 of 3,528 patients in STEEPLE. Patients with (n = 103) and without (n = 3,239) hematomas ≥5 cm were evenly distributed across treatment groups.

Results

No differences were observed in 30-day ischemic outcomes between patients with and without hematomas (5.8% vs 5.9%, respectively; P = .96). No transfusions were observed in patients with hematomas as compared with patients without hematomas (0% and 0.4%, respectively; P = .52). A greater reduction in hemoglobin was observed (pre- vs post-PCI) in patients with hematomas as compared with patients without hematomas (−0.84 vs −0.35 g/L, P ≤ .001). No significant difference in all-cause 1-year mortality was observed between patients with and without hematomas (0.0% vs 1.7%, P = .98).

Conclusions

After PCI, hematomas ≥5 cm had no effect on 30-day ischemic events or 1-year mortality. Although there is no agreed classification for large hematomas, the lack of a relationship between hematomas ≥5 cm and clinical outcome after PCI justifies the classification of these hematomas as minor bleeds in STEEPLE.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 RCT#: NCT00077844.


© 2010  Mosby, Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 159 - N° 1

P. 110-116 - Gennaio 2010 Ritorno al numero
Articolo precedente Articolo precedente
  • EuroSCORE refines the predictive ability of SYNTAX score in patients undergoing left main percutaneous coronary intervention
  • Davide Capodanno, Marco Miano, Glauco Cincotta, Anna Caggegi, Cettina Ruperto, Rita Bucalo, Alessandra Sanfilippo, Piera Capranzano, Corrado Tamburino
| Articolo seguente Articolo seguente
  • Safety and feasibility of early hospital discharge in ST-segment elevation myocardial infarction—A prospective and randomized trial in low-risk primary percutaneous coronary intervention patients (the Safe-Depart Trial)
  • Mark A. Kotowycz, Tammy L. Cosman, Corinne Tartaglia, Rizwan Afzal, Renu Pal Syal, Madhu K. Natarajan

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.